Results 51 to 60 of about 13,054 (213)

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 990-1004, July 2026.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source

Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells

Molecular Cancer, 2008
Background Histone acetylation is an epigenetic modification involved in the regulation of gene expression, balanced by histone acetyl transferases and histone deacetylase (HDAC) enzymes.
Dejligbjerg Marielle, Grauslund Morten, Litman Thomas, Collins Laura, Qian Xiaozhong, Jeffers Michael, Lichenstein Henri, Jensen Peter, Sehested Maxwell   +8 more
doaj   +1 more source

Synthesis and Characterization of HDACi Derivatives and Pt Complexes

, 2023
Histone deacetylase (HDAC) enzymes are overexpressed in several types of cancer cells, leading to the application of HDAC inhibitors (HDACi), such as vorinostat, as anticancer agents.
Lu, Chris, Stahl, Jayden, Do, Phuc, Patel, Raj   +3 more
core   +1 more source

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition

Advanced Science, Volume 13, Issue 32, 9 June 2026.
The authors engineer colorectal cancer cells with reduced redundancy of UHRF1 and DNMT1, key DNA methylation maintenance factors, lowering the maintenance threshold and sensitizing cells to inhibition. They develop reporter assays driven by endogenous tumor‐suppressor gene promoters with enhanced sensitivity and dynamic range to demethylating drugs ...
Cuicui Xia, Ying Cui, Jiongliang Wang, Wenjing Bai, Danyang Wang, Yao Chen, Huahui Guo, Liangyi Zong, Bing Qin, Xintong Cai, Jie Wang, Jing Huang, Scott B. Rothbart, Zufeng Guo, Stephen B. Baylin, Xiangqian Kong   +15 more
wiley   +1 more source

Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors.

PLoS ONE, 2012
Histone deacetylase inhibitors (HDACi) are increasingly used as therapeutic agents, but the mechanisms by which they alter cell behaviour remain unclear.
John Halsall, Vibhor Gupta, Laura P O'Neill, Bryan M Turner, Karl P Nightingale   +4 more
doaj   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, Volume 13, Issue 35, 24 June 2026.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

An epigenetic vaccine model active in the prevention and treatment of melanoma

Journal of Translational Medicine, 2007
Background Numerous immune genes are epigenetically silenced in tumor cells and agents such as histone deacetylase inhibitors (HDACi), which reverse these effects, could potentially be used to develop therapeutic vaccines.
Magner William J, Khan A Nazmul H, Tomasi Thomas B   +2 more
doaj   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies: An Umbrella Review of Systematic Reviews and Meta‐Analyses

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background This umbrella review summarizes evidence from systematic reviews and meta‐analyses on the efficacy and safety of immune checkpoint inhibitors (ICIs) in hematologic malignancies. To our knowledge, this is the first umbrella review to comprehensively evaluate ICIs across multiple hematologic cancers.
Zhengyu Yu, Zhongwang Wang, Li Xie, Jing Xu, Lang Min, Lingfeng Li, Ting Niu   +6 more
wiley   +1 more source

HDACi and Nrf2: not from alpha to omega but from acetylation to OA [PDF]

Arthritis Research & Therapy, 2015
Arthritis Research & Therapy 17(1), 381 (2015).
openaire   +3 more sources

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Pharmaceuticals, 2010
Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease.
Roberto Pili, Leigh Ellis
doaj   +1 more source